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Objectives. To survey practice variation in the management of first trimester miscarriage inThe Netherlands.Methods. We sent an
online questionnaire to gynecologists in eight academic, 37 nonacademic teaching, and 47 nonteaching hospitals. Main outcome
measures were availability of a local protocol; estimated number of patients treated with curettage, misoprostol, or expectant
management; misoprostol regimen; and estimated number of curettages performed after initial misoprostol treatment. Outcomes
were compared to the results of a previous nationwide survey. Results. The response rate was 100%. A miscarriage protocol
was present in all academic hospitals, 68% of nonacademic teaching hospitals, and 38% of nonteaching hospitals (𝑃 = 0.008).
Misoprostol was first-choice treatment for 41% of patients in academic hospitals versus 34% and 27% in teaching-and nonteaching
hospitals (𝑃 = 0.045). There were 23 different misoprostol regimens. Curettage was first-choice treatment in 29% of patients in
academic hospitals versus 46% and 50% in nonacademic teaching or nonteaching hospitals (𝑃 = 0.007). In 30% of patients, initial
misoprostol treatment was followed by curettage. Conclusions. Although the percentage of gynaecologists who are aware of the
availability of misoprostol for miscarriage treatment has doubled to almost 100% since 2005, practice variation is still large. This
practice variation underlines the need for a national guideline.
1. Introduction
First trimester miscarriage is a frequent complication of
pregnancy which occurs in 10–15% of pregnant women. In
The Netherlands, this results in 18,000 to 27,000 miscarriages
each year [1]. Because of the increased use of first trimester
ultrasounds, ever more often the diagnosis nonvital preg-
nancy is made before symptoms occur [2]. In the past, Dutch
women diagnosed with nonvital pregnancy either were man-
aged expectantly, with complete expulsion of the pregnancy
known to occur within two weeks in 37% of women, or were
offered curettage [3]. However, in recent years, medical treat-
ment with misoprostol has been shown to be an easy-to-use
and inexpensive treatment option, which is well received
by patients wishing to avoid surgical treatment. Treatment
with misoprostol is effective in 53–99% of women with
miscarriages, depending on dosage, route of administration,
and duration of follow-up [4–8]. There are no significant
differences between the use of misoprostol versus curettage
on the rate of pelvic infections or ongoing subsequent preg-
nancies [9, 10].Despite the high incidence ofmiscarriages and
the developments in miscarriage treatment, a guideline from
the Dutch Society of Obstetrics and Gynecology (NVOG) is
still lacking. A national survey in 2005 among gynecologists
in 92 hospitals that focused mainly on induced abortion
but also studied spontaneous miscarriage showed that about
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50% of Dutch gynecologists offered misoprostol as treatment
option for first trimester miscarriages. However, there was a
large practice variation with 27 different regimens being used
for treatment of nonvital pregnancies [11]. Misoprostol could
be a good alternative for curettage as first-choice treatment,
but, to increase its effectiveness nationwide, all hospitals
should offer the same clinically proven treatment regimens.
In the present study, we investigated the current practice
in miscarriage treatment in Dutch hospitals. Our aim was
to survey the practice variation and especially to monitor
the implementation of misoprostol, compared to the earlier
survey performed in 2005.
2. Methods
We developed an online questionnaire which was sent by e-
mail to practicing obstetricians and gynecologists in allDutch
hospitals, that is, eight academic, 37 nonacademic teaching,
and 47 nonacademic nonteaching hospitals.Thefirstmail was
sent in December 2012, and reminders were sent monthly to
nonresponders up until April 2013.
The questionnaire inquired about the estimated number
of miscarriages per year, available treatment options, and
the presence of a local protocol for managing miscarriages.
Furthermore, we inquired how patients were informed about
various treatment options, for example, by written informa-
tion and/or by online information from the hospital’s website.
Whenever medical treatment was offered, we asked for
the dosages used, the route of administration, and the pos-
sible additional use of the antiprogesterone mifepristone. We
also asked what percentage of patients underwent curettage
after misoprostol use and what the main reason was for this
intervention.
Analysis was performed per type of hospital: results of
academic hospitals, nonacademic teaching hospitals, and
nonteaching hospitals were compared. If estimated patient
numbers provided by multiple respondents from the same
hospital differed, we used the mean number in the analysis;
incomplete and missing data were excluded from analysis.
Whenever possible, we compared the outcomes of the
present questionnaire to the earlier nationwide survey, per-
formed in 2005 and published in 2010. This previous study
focussed mainly on induced abortion but also provided
information on treatment of spontaneous miscarriage.
Chi-square tests and Fisher’s exact test were used to com-
pare categorical variables. To analyse differences in the use of
misoprostol as first-choice treatment the Mann-Whitney 𝑈
test was applied. A 𝑃 value < 0.05 was considered significant.
All statistical analyses were done using the statistical package
for social sciences (SPSS, IBM, Chicago, IL, USA) version
20.0. Since patients were not involved, approval by a medical
ethics committee was not necessary for this study.
3. Results
The response rate to the questionnaires was 100% (𝑛 =
92): in all hospitals at least one gynecologist completed the
questionnaire. A miscarriage protocol was present in all
academic hospitals versus 68% of the teaching hospitals and
38% of the nonteaching hospitals (𝑃 = 0.008 for academic
versus nonacademic hospitals).
The median number of women with a miscarriage per
hospital per year was 150 (IQR 100–300) in the academic hos-
pitals, 200 (IQR 150–250) in nonacademic teaching hospitals,
and 120 (IQR 100–200) in nonteaching hospitals. Annually,
approximately 1050 women with an early pregnancy loss
presented in the academic hospitals, compared to 6600
women in teaching hospitals and 6550women in nonteaching
hospitals. All academic hospitals offered misoprostol as a
treatment option compared to 97.3% of teaching hospitals
and 95.7% of nonteaching hospitals. All hospitals offered
expectant management and curettage as treatment options to
their patients.
According to our respondents, in total, 49% of women
underwent curettage as first-choice treatment; 31% of women
were treated with misoprostol, while 21% were managed
expectantly in the past year. Curettage was first-choice treat-
ment in 29% of patients in academic hospitals versus 46%
and 54% of patients in teaching and nonteaching hospitals,
respectively (𝑃 = 0.007 academic versus nonacademic).
Misoprostol was first-choice treatment in 41% of patients
in academic hospitals versus 34% and 27% of patients in
teaching and nonteaching hospitals. There was a significant
difference between academic and nonteaching hospitals (𝑃 =
0.045). Expectant management was first-choice treatment in
30% of patients in academic hospitals versus 20% and 19% of
patients in teaching and nonteaching hospitals (Table 1).
For treatment with misoprostol, 23 different regimens
were being used. In 15 hospitals, more than one regimen was
used. Misoprostol was administered vaginally by 7/8 (87.6%)
of academic hospitals, 36/37 (97.3%) of nonacademic teaching
hospitals, and 39/47 (83.0%) of nonteaching hospitals. Oral
administrationwas used by 3/8 (37.6%) of academic hospitals,
5/37 (13.5%) of nonacademic teaching hospitals, and 15/47
(31.9%) of nonteaching hospitals. The combination of oral
followed by vaginal administrationwas used by 2/8 (25.0%) of
academic hospitals and 9/47 (19.1%) of nonteaching hospitals
(Table 2).The initial misoprostol dosages ranged from 200 to
1200𝜇g.
The preferred method of 51 hospitals was a vaginal
dose of 800𝜇g, which was applied in 63% of the academic
hospitals, in 62% of the teaching hospitals, and in 47% of the
nonteaching hospitals (𝑃 = 0.89). In case of no or incomplete
expulsion of the miscarriage after the first dose, a repeat dose
was administered in all academic hospitals and in 84% and
72% of the teaching and nonteaching hospitals (𝑃 = 0.32
academic versus nonacademic). A large variation existed in
both the frequency and dosage of misoprostol gifts. One
academic hospital applied 400 𝜇g of misoprostol twice daily
during two days, and one academic hospital applied a once-
only repeat dose of 400 𝜇g.The other academic hospitals used
repeat doses of 800 𝜇g. Five nonacademic hospitals applied
a dosage of 400 𝜇g twice daily, for at least two days. One
of these hospitals prescribed 400 𝜇g of misoprostol twice
daily for five days. Of nonacademic hospitals, 39/84 (46%)
applied repeat dosages of 800 𝜇g once only, three hospitals
(3.6%) of 600𝜇g, and seven hospitals (8.3%) of 400 𝜇g. Other
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Table 1: Mean number of patients (in percentages) per different treatment options.
Academic (𝑁 = 8) Nonacademic, teaching (𝑁 = 37) Nonteaching (𝑁 = 47)
% SD % SD % SD
Curettage 29 11 46a 20 54a 20
Misoprostol 41b 8,3 34 20 27 17
Expectant management 31b 8,5 20 15 20 12
aCurettage as primary treatment, academic versus nonacademic teaching hospitals: 𝑃 = 0.028 and academic versus nonacademic nonteaching hospitals: 𝑃 =
0.002 (Mann-Whitney 𝑈 test).
bMisoprostol as a primary treatment, academic versus nonteaching hospitals: 𝑃 = 0.045 (Mann-Whitney 𝑈 test).
cExpectant management as primary treatment, academic versus nonteaching hospitals: 𝑃 = 0.023 (Mann-Whitney 𝑈 test).
All other comparisons: NS.
Table 2: The route of administration and dosage of misoprostol according to local protocols.
Academic (𝑁 = 8) Nonacademic, teaching (𝑁 = 36) Nonteaching (𝑁 = 46)
𝑛 % 𝑛 % 𝑛 %
Vaginal 7 87.6 34 91.9 41 89.1
200 𝜇g 0 0.0 2 5.6 4 8.7
400 𝜇g 2 25.0 6 16.7 10 21.7
600 𝜇g 0 0.0 3 8.3 3 6.5
800 𝜇g 5 62.5 23 63.9 23 50.0
1200 𝜇g 0 0.0 0 0.0 1 2.2
Oral 3 37.5 3 8.3 13 28.3
200 𝜇g 0 0.0 0 0.0 4 8.7
400 𝜇g 1 12.5 2 5.6 3 6.5
600 𝜇g 1 12.5 0 0.0 4 8.7
800 𝜇g 1 12.5 1 2.8 2 4.3
Oral followed by vaginal 0 0.0 0 0.0 4 8.7
200 𝜇g + 800 𝜇g 0 0.0 0 0.0 1 2.2
400 𝜇g + 600 𝜇g 0 0.0 0 0.0 1 2.2
600 𝜇g + 600𝜇g 0 0.0 0 0.0 2 4.3
Repeat dose given 8 100.0 31 83.8 34 72.3
dosages mentioned were once-only repeat dosage of 200 𝜇g
(𝑛 = 4), once-only repeat dosage of 1200 𝜇g (𝑛 = 1), and
800 𝜇g twice daily during 2 days (𝑛 = 1). One nonteaching
hospital reported that, as part of routine, almost all patients
underwent a curettage after their first dosage of 400 𝜇g
misoprostol.
The addition of mifepristone to the treatment with miso-
prostol was applied in 38% of the academic hospitals, 27% of
the teaching hospitals, and 45% of the nonteaching hospitals
(𝑃 = 0.47).
In 30% of patients, initial treatment with misoprostol was
followed by curettage (academic hospitals median 25%, IQR
25–35; nonacademic teaching hospitals median 30%, IQR
20–50; nonteaching hospitals median 30%, IQR 20–50). The
main reasons for performing curettage after initial medical
treatment with misoprostol were the sonographic finding of
incomplete evacuation of the uterus (84.8%) and/or excessive
blood loss (54.3%). In 25% of cases curettages after initial
medical treatment were performed on patients’ request only,
despite the lack ofmedical reasons (i.e., persisting or excessive
blood loss, pain, and/or fever).
In comparison to the survey performed in 2005, the
number of clinics prescribing misoprostol for first trimester
miscarriage has doubled. Any other comparison could not
be made since the 2005 survey focussed on the use of
misoprostol for induced abortion.
The most important method for counselling patients
about various treatment options was oral information (pro-
vided by 100% of the hospitals). In 81.5% of hospitals,
gynecologists also referred women to informative websites.
In addition, 65.2% of hospitals provided a leaflet with written
information.
4. Discussion
In this study, we investigated the current practice in miscar-
riage treatment in Dutch hospitals and especially the imple-
mentation of misoprostol treatment. Our main findings were
that there is a large practice variation. Despite the availability
of noninvasive and cost-effective alternatives, curettage is
still the first-choice treatment in 49% of patients. When
misoprostol is offered as treatment, the regimens in terms of
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dosage, frequency of administration, administration routes,
and addition of mifepristone vary largely between hospitals.
Although academic, teaching, and nonteaching hospitals
generally provide care for different types of patients, this is
generally not the case where miscarriages are concerned. We
do not think it is likely that bias was introduced by patient
characteristics.
We inquired about the estimated number of miscarriages
per year, the provided treatment options, and the distribution
of patients among these management options. Although
gynaecologists were asked to provide exact numbers if avail-
able, most respondents provided us with estimated numbers
instead of exact data. Since the response rate was 100%,
we believe that our findings are the second best indicator
for current practice in The Netherlands, where a central
registration of nonsurgical treatment is not available.
RCOG (NICE) [2] and FIGO [12] have guidelines
addressing management of miscarriages and misoprostol use
that are applicable to Dutch practice. A possible explanation
for the lack of such a guideline in The Netherlands is the
divided care for pregnant women. In case of a miscarriage,
medical or surgical treatment is always performed by an
obstetrician or gynaecologist, but expectant management
also takes place in primary care (general practitioner or
midwife). In some hospitals, miscarriage treatment is some-
times considered an obstetrical problem, whereas, in other
hospitals, it is part of the department of gynecology and/or
reproductive medicine. The high response rate to our ques-
tionnaire indicates that the subject is considered important
by most gynaecologists in The Netherlands. With so many
caretakers involved in the treatment of miscarriage, it could
be that no one in particular feels the responsibility to initiate a
multidisciplinary guideline. Creating a guideline for andwith
all these caretakers is a difficult task.
Compared to the earlier survey in 2005 [11], the number
of hospitals offering misoprostol doubled. This treatment
implementation however was not coordinated by the NVOG
or another national institute, which results in the use of
more than 20 different local protocols regarding medical
treatment.Themost frequently describedmisoprostol dosage
in literature is a vaginal dose of 800𝜇g, which can be repeated
after 24 to 48 hours in case of nonexpulsion after the first
dose [4–9, 13, 14]. The NICE guideline “Ectopic Pregnancy
and Miscarriage” by the Royal College of Obstetricians and
Gynaecologists (RCOG, 2012) advises giving a single dose of
800 𝜇g misoprostol vaginally or orally according to patients’
preference [2].
The International Federation of Gynecology and Obstet-
rics (FIGO) advises giving 800 𝜇g misoprostol vaginally or
600𝜇g sublingual, with a repeat dose after 3 hours (maximum
of 2 doses) according to a practice bulletin in 2012 [12].
Despite not being distributed actively toDutch gynecologists,
these guidelines and the research on which they are based
are easily accessible. However, a distressing number of local
protocols in The Netherlands still seem to be based on
personal preference or experience since there is no evidence
in literature for the efficacy of their misoprostol regimens.
When we asked gynecologists for misoprostol regimens used
in their hospitals, we found that, in 15 hospitals, more than
one regimen was used. We did not ask the gynecologists
for the reasons of using different regimens. An explanation
for this nonadherence to a local protocol might be personal
preference of the patient. For example, if a patient does not
want to take vaginal medication, oral medication is pre-
scribed.There might be a lack of knowledge because of insuf-
ficient implementation of the local protocol. Furthermore, a
negative experience of the individual gynecologist with the
dosages mentioned in the local protocol can lead to deviation
from this protocol. Adosage of 800𝜇gmisoprostol is themost
effective according to literature. Treatment regimens that are
suboptimal because the dosage used is higher than 800𝜇g or
lower than 600 𝜇g [2, 12, 14], lead to over- or under treatment
of a large group of patients, and deprive these patients from
the most efficacious and patient friendly treatment.
A reason why many gynecologists are still reluctant in
offering medical treatment might be the risk of incom-
plete evacuation of the uterus. This occurs in 20–30% of
patients treated with misoprostol [4–9, 13]. We did not ask
for time duration between misoprostol administration and
sonographic follow-up. This might influence the success rate
of the treatment. Many cases with sonographic signs of
incomplete miscarriage do not evolve into serious clinical
problems, such as excessive bleeding, pain, or infection,
but are likely to resolve spontaneously. Results of a ran-
domized clinical trial comparing curettage with expectant
management in case of incomplete evacuation of the uterus,
the MisoREST trial (NL38637.018.11), are awaited in 2015
[15]. If expectant management turns out to be safe and
effective, this could potentially save another 3000 surgical
procedures (i.e., curettages) in The Netherlands each year.
Furthermore, clear evidence on this subject might lead to a
further implementation of misoprostol treatment.
Literature on addition of 200mg oral mifepristone 24
to 48 hours before misoprostol treatment for miscarriage
showed conflicting results [14, 16]. To evaluate the efficacy
of mifepristone prior to treatment with misoprostol for a
nonvital pregnancy, a new trial (M&Mtrial, NL43938.091.13)
will start soon.
There are no differences between the use of misoprostol
and curettage with regard to the duration of blood loss,
the risk of pelvic infections, and subsequent fertility [9,
10, 13]. Treatment with misoprostol is more cost effective
than primary curettage [17, 18]. Despite this, nonacademic
hospitals significantly more often applied curettage as first-
choice treatment compared to academic hospitals. This
might result from infrastructural differences between smaller
nonacademic hospitals and academic hospitals which have
longer waiting lists. Furthermore, expectant management or
misoprostol treatment requires more visits to the outpatients
department. Another explanation is that academic hospitals
are more aware of international research findings and the
implementation of their results and therefore aremorewilling
to adopt new treatment strategies. Also, the insurance system,
where the financial compensation differs between surgical
and medical treatment, could play a role. This might explain
the relatively slow implementation of medical management
in daily practice, despite its being a noninvasive and cost-
effective option. This is also unfortunate in view of other
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disadvantages of curettage. A cost-effectiveness analysis in
Dutch hospitals showed the costs of first-choice misoprostol
treatment to be C 550 lower than the costs of first-choice
curettage [17]. We think that this cost difference is appli-
cable to the current situation in other developed countries.
According to our results, an estimated number of 10000
women undergo a curettage as first-choice treatment each
year. If these women would be treated with misoprostol
instead, assuming an effectiveness of 90%, this would prevent
9000 women from undergoing a curettage thereby saving
almost 5 million euros per year in The Netherlands only.
One can imagine that the potential savings worldwide are
considerable.
Besides the costs, there are even more important reasons
not to perform curettage as a first-choice treatment. There is
no doubt that a curettage is effective, but it has potentialmajor
disadvantages: there is a risk of short term complications
like uterus perforation or infections and long term compli-
cations. 19% of women with a history of curettage develop
intrauterine adhesions varying from mild to severe [19].
Furthermore, there is accumulating evidence that women
with a history of curettages are at increased risk of preterm
birth in subsequent pregnancies [20, 21]. Therefore, we think
expectant management or misoprostol treatment should be
first choice because of their noninvasive nature, which is in
line with the recommendations of the NICE guideline to use
expectant management for 7–14 days as first-line treatment,
offer medical management if expectant management is not
acceptable to the woman, and perform curettage as primary
treatment in exceptional cases only [2].
The large practice variation and the difficulties in sub-
stituting medical for surgical treatments are not restricted
to miscarriage treatment only. For example, implementation
of nonsurgical treatment of uterine fibroids was also delayed
despite evidence of its effectiveness [22].
The slow uptake of misoprostol treatment for miscarriage
is an international issue, which is not restricted to The
Netherlands alone. This might be explained by concerns
about infection, which, although not supported by data,
withhold healthcare providers from using misoprostol, or by
differences in reimbursement between medical and surgical
treatment. Globally, it is very likely that societal and political
forces impact decisions of health care providers on the use
of misoprostol. In some countries, antiabortion activists have
succeeded in creating the view that misoprostol use may be
unlawful, as it is related to use for abortion of pregnancies,
which has led to delayed implementation of misoprostol
treatment for miscarriages [23].
Apart from access to all treatment options for mis-
carriage, the preference of the patient is important and
obviously should play a decisive role in the final treatment
choice. Therefore, the patient needs to be informed about
the effectiveness and risks of all treatment options. Negative
experiences of caregivers with medical treatment of mis-
carriage, which might be based on substandard regimens,
could influence this counselling.Therefore, all gynaecological
caregivers should have knowledge about best treatment
regimens, which can be achieved by implementation of an
up-to-date guideline. This does not apply toThe Netherlands
only. The World Health Organization (WHO) has included
misoprostol in the WHO Model List for Essential Medicines
because of its importance in reproductive health and provides
recommendations for its use for obstetric and gynecologic
indications [24, 25]. As misoprostol is inexpensive, stable at
room temperature, and worldwide available, it is also very
useful in undeveloped countries [25].
There is little literature on guideline adherence regarding
miscarriage treatment. A Scottish survey published in 2006
showed areas of improvement for guideline implementation
[26]. Eight years later, despite WHO recommendations, not
all countries have implemented a guideline on miscarriage
treatment. This leads to practice variation and unnecessary
(surgical) treatment, as our study indicates.
5. Conclusion
Although the percentage of gynaecologists that are aware
of the availability of misoprostol for miscarriage treatment
doubled from 50% in 2005 to virtually 100% in 2013, there
is still a large practice variation. In the absence of a guide-
line, a large number of hospitals still use local protocols
for misoprostol treatment that are not evidence based. In
nonacademic hospitals, curettage is still primary treatment in
50% of patients despite its potential major disadvantages.
The development and implementation of a national
guideline or adoption of an international guideline might
prevent women from having an unnecessary curettage. Fur-
thermore, it could reduce practice variation and lead to better
overall treatment results and patients satisfaction in women
treated with misoprostol.
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